Regulatory Japan’s MHLW approves Boehringer’s Jascayd for IPF and PPF Pharmaceutical TechnologyBoehringer Ingelheim has received Japan's MHLW approval for Jascayd (nerandomilast) to treat adults with IPF and PPF.RespiratoryRead full story pharminent May 18, 2026 (Last updated: May 21, 2026) Pharmaceutical Technology Boehringer Ingelheim has received Japan’s MHLW approval for Jascayd (nerandomilast) to treat adults with IPF and PPF. Respiratory Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Another LAG-3 setback as Regeneron drug fails phase 3 trialNext: Japan’s MHLW approves Boehringer’s Jascayd for IPF and PPF Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
